Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
|Podcasts|August 28, 2016
Podcast: Margaret E. O'Kane Discusses Her Pioneering Work on Quality Measurement
Author(s)Laura Joszt, MA
In this podcast Margaret E. O'Kane discusses how she got into quality measurement, the beginning of the National Committee for Quality Assurance, and the next frontier in quality measurement.
Advertisement
For the 11th year in a row, Margaret E. O'Kane, president of the National Committee for Quality Assurance (NCQA), has been named to Modern Healthcare's 100 Most Influential People in Healthcare list. Throughout her career, she has been committed to ensuring healthcare quality through measurement, transparency, and accountability.
Listen to O'Kane discuss how she got into quality measurement, the beginning of NCQA, and the next frontier in quality measurement.
Advertisement
Related to this article
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
5